Elsevier

European Urology

Volume 44, Issue 4, October 2003, Pages 407-414
European Urology

Multiple Vesico-Urethral Biopsies Following Radical Prostatectomy: The Predictive Roles of TRUS, DRE, PSA and the Pathological Stage

https://doi.org/10.1016/S0302-2838(03)00320-8Get rights and content

Abstract

Introduction: The aim of this study is to verify the predictive role of transrectal ultrasound (TRUS) of prostatic fossa, digital rectal examination (DRE), prostate specific antigen (PSA) and pathological stage after radical prostectomy in the detection of a prostate tumor recurrence at the level of the vesico-urethral anastomosis by means of multiple TRUS biopsies (6–8 cores).

Material and Methods: From October 1997, following a radical prostatectomy, 119 consecutive patients (median age: 67.9 years) with a PSA≥0.2 ng/ml (median PSA: 0.9 ng/ml) underwent DRE and TRUS examinations with a 5.0–7.5 MHz variable frequency end-fire probe (Hitachi Medical System) and an EUB-525 machine. All patients received six TRUS-guided biopsies of the vesico-urethral anastomosis, and 1–2 additional biopsies directed to hypo-echoic or suspicious areas, if detected by TRUS.

Results: Biopsies revealed recurrent carcinoma in 50% of patients (60/119). TRUS proved more sensitive than DRE (75% vs. 50%; p=0.01) and, conversely, DRE proved more specific than a TRUS (85% vs. 66%; p=0.03). Cancer was detected in 45% of the 34 patients with a PSA≤0.5 ng/ml. In the group of patients with a PSA≥2.0 ng/ml (24 patients), TRUS was able to detect every biopsy-proven local recurrence lesion (sensitivity: 100%). Conversely, all patients with a PSA≥2.0 ng/ml and a negative TRUS had a negative biopsy (negative predictive value: 100%). In a multi-variable logistical analysis, the most predictive parameters determining a positive biopsy rate among those values studied (PSA, DRE, TRUS, positive surgical margins, pathological stage and time to PSA elevation) were TRUS and DRE findings (p=0.003, with an odds ratio of 4.6 and p=0.02, with an odds ratio of 4.1, respectively).

Conclusion: TRUS and TRUS biopsies utilizing 6–8 cores are efficient tools in the detection of local recurrence after a radical prostatectomy, even with a PSA≤0.5 ng/ml. A combination of TRUS and DRE findings seems to predict biopsy results best. In case of a PSA≥2.0 ng/ml and a negative TRUS, a biopsy of the vesico-urethral anastomosis could be avoided since the negative predictive value is 100%. Cancer recurrence detection seems to be predicted by TRUS and DRE findings, but not by PSA levels, pathological stage, status of the surgical margins or time to PSA elevation.

Introduction

After radical prostatectomy, transrectal ultrasound (TRUS) of the vesico-urethral anastomosis is generally considered to be an accurate diagnostic procedure in detecting prostate cancer recurrence because it provides a precise evaluation of the normal and pathological prostatic fossa anatomy [1], [2]. Particularly in cases of low PSA levels or cranial disease in proximity of the bladder neck, a TRUS, despite being less specific, is considered more sensitive than a digital rectal examination (DRE) [3].

The clinical need to perform a TRUS biopsy of the vesico-urethral anastomosis before treatment, in the event of a PSA failure, is still under investigation [1], [2]. Moreover, the decision regarding local radiation therapy after a radical prostatectomy is generally taken without documentation of recurrent local disease [1]. One main concern is the relative inability of a TRUS and a TRUS biopsy to detect local recurrence with a PSA<1 ng/ml [4] and the need to wait for a subsequent PSA increase in order to obtain a biopsy-proven local recurrence before proceeding with radiotherapy [5], [6]. Until a positive biopsy has been determined, a time delay in performing salvage radiotherapy is considered dangerous [6]. Nevertheless, a positive biopsy seems to be a good prognostic factor in terms of response after radiotherapy [7]. Several investigators have produced better results when using external-beam radiation in patients with local prostate cancer recurrence documented by biopsies, the suggestion being to use radiation therapy only in cases of a positive biopsy [8], [9], [10].

Following a radical prostactectomy, the predictive role of a positive TRUS of the prostatic fossa or the PSA level or the pathological stage is still unclear, and data from literature are controversial. Some authors have shown that cancer recurrence detection by means of the biopsy of the anastomosis seems to be correlated only to TRUS findings [3], and others to PSA levels and the pathological stage at the time of a radical prostatectomy [11].

The aim of this study is to verify the diagnostic accuracy of a transrectal ultrasound (TRUS) in the detection of vesico-urethral anastomosis tumour recurrence via multiple biopsies (6–8 cores) according to TRUS, DRE findings and PSA levels, with special attention given to patients with a PSA level ≤ 0.5 ng/ml. A statistical model has been constructed to predict the recurrence detection probability of each parameter studied.

Section snippets

Material and methods

Starting October 1997, 128 TRUS-guided prostatic fossa biopsies were carried out in 119 consecutive patients (median age ± S.D.: 67.9±5.7 years) who had a sustained serum elevation of PSA≥0.2 ng/ml (median PSA: 0.89 ng/ml) following a radical prostatectomy or a palpable abnormality in the anastomosis area. Serum PSA levels were measured by using a radio-immunoassay (Tandem-R, Hybritech, USA). DRE findings were considered abnormal if any mass, nodule, hardness or irregularity was noted in the

Results

Five patients underwent more than one biopsy session: results of the repeated biopsies were excluded from analysis because of the small patient group. In the 119 patients evaluated, the mean PSA at the time of the TRUS biopsies was 1.8±3.7 ng/ml (range 0.2–28.8 ng/ml). DRE was positive in 37 patients (31%) and TRUS-detected, suspicious lesions in 64 cases (54%). Biopsies revealed recurrent carcinoma in 50% of patients (60/119). The detection rates according to the DRE and TRUS findings are

Discussion

Since its introduction in the early 1980s, TRUS has developed its imaging capabilities right up till today’s most powerful ultrasound machines, encompassing new technological methods such as Colour Doppler, Power Doppler and three-dimensional imaging [1]. Thus, the ability to diagnose prostate cancer and prostate cancer recurrence in the prostatic fossa has become greater thanks to the parallel development of transrectal ultrasound (TRUS) and TRUS-guided prostate biopsies. Initially, Wasserman

Conclusions

TRUS and TRUS-biopsy with 6–8 cores are efficient tools in the detection of local recurrence after a radical prostatectomy, even with a PSA<0.5 ng/ml. TRUS hypo-echoic lesions were positive at biopsy in over 65% of the cases; on the contrary, 34% of local recurrence was not visible with a TRUS. The combination of TRUS and DRE findings seems to predict biopsy findings best. The bladder neck is the site where tumour relapse is less visible, while the lesion site with the highest positive

References (24)

Cited by (65)

  • Postoperative radiotherapy in prostate cancer: The case of the missing target

    2012, International Journal of Radiation Oncology Biology Physics
    Citation Excerpt :

    There is a paucity of literature investigating the sites and spatial distribution of local relapses in prostate cancer patients treated with radical prostatectomy. Initial MRI and transrectal ultrasound (TRUS) studies suggested that most local recurrences occur in the perianastomotic region (21, 25–28). A more recent study by Sella et al. has been published demonstrating the efficacy of endorectal coil MRI in locating local relapses in the postoperative setting on a retrospective series of patients (19).

View all citing articles on Scopus
View full text